NEW YORK, NY--(Marketwire -07\/19\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Anthera Pharmaceuticals Inc. (ANTH) and Peregrine Pharmaceuticals (PPHM). <\/p>\n
Access to the full company reports can be found at: <\/p>\n
http:\/\/www.ParagonReport.com\/ANTH<\/a> http:\/\/www.ParagonReport.com\/PPHM<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Anthera Pharmaceuticals a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, recently announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus. Shares of the company soared over 20 percent Tuesday. <\/p>\n Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing and manufacturing innovative monoclonal antibody therapeutics for the treatment of cancer and viral infections. The company recently reported fourth quarter and fiscal year 2012 results, and provided a positive outlook for their drug candidates. Shares of the company surged over 25 percent Tuesday. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Read more: NEW YORK, NY--(Marketwire -07\/19\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Anthera Pharmaceuticals Inc Continue reading
\nAnthera Pharmaceuticals and Peregrine Pharmaceuticals Set for Growth as Biotech Industry Soaring in 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"